(TGD) Addresses Sentry Investments Press Release

Timmins Gold Corp.
Alex Tsakumis
Vice President, Corporate Development
604-604-682-4002
alex@timminsgold.com
www.timminsgold.com

(BRCM) to Explore Strategic Alternatives for Cellular Baseband Business

Company Accelerates Key Initiatives in Broadband, Infrastructure and Connectivity Markets Conference Call Webcasted at 6:00 a.m. PT / 9:00 a.m. ET www.broadcom.com/investors

IRVINE, Calif., June 2, 2014  — Broadcom Corporation (NASDAQ: BRCM), a global innovation leader in semiconductor solutions for wired and wireless communications, today announced it is exploring strategic alternatives for its cellular baseband business, including a potential sale or wind-down. The company has engaged investment bank JP Morgan in connection with its efforts.

The successful sale or wind-down of the cellular baseband business is currently expected to result in a roughly $700 million reduction in annualized GAAP research and development and selling, general and administrative expenses, of which approximately $100 million relates to estimated reductions in stock-based compensation. As such, non-GAAP research and development and selling, general and administrative expenses are currently expected to be reduced by roughly $600 million.  These estimates do not reflect the impact of any potential impairment and/or restructuring charges that are likely to be recorded related to the successful sale or wind-down of Broadcom’s cellular baseband business.

Broadcom currently expects to organically reinvest roughly $50 million of these savings on an annualized basis into projects in the Broadband, Infrastructure and Connectivity businesses. This incremental spending is currently expected to strengthen and accelerate the company’s plans in the area of small cells, embedded processing and low-power connectivity.

Updated Business Outlook

Broadcom today also updated its business outlook for the three months ending June 30, 2014. Broadcom continues to expect revenue between $2.0 billion and $2.1 billion. Broadcom now expects both GAAP and non-GAAP product gross margin to be at or above the high end of the previously-guided range, driven principally by mix.

Conference Call Information

Broadcom will conduct a conference call with analysts and investors today at 6:00 a.m. PT (9:00 a.m. ET). Interested parties can call (800) 447-0521 US toll free or (847) 413-3238 US toll. The company will broadcast the conference call via webcast over the Internet. To listen to the webcast, please visit the Investors section of Broadcom’s website at www.broadcom.com/investors. The webcast will be recorded and available for replay, within 48 hours after the event, until 10:00 p.m. PT on July 2, 2014.

There can be no assurance that this exploration process will result in a sale. The company does not intend to discuss developments with respect to the exploration of strategic alternatives in cellular baseband unless or until its Board of Directors has approved a definitive transaction or the process is otherwise complete.

About Broadcom

Broadcom Corporation (NASDAQ: BRCM), a FORTUNE 500® company, is a global leader and innovator in semiconductor solutions for wired and wireless communications. Broadcom® products seamlessly deliver voice, video, data and multimedia connectivity in the home, office and mobile environments. With the industry’s broadest portfolio of state-of-the-art system-on-a-chip solutions, Broadcom is changing the world by Connecting everything®. For more information, go to www.broadcom.com.

Cautions Regarding Forward-Looking Statements

All statements included or incorporated by reference in this release and the related conference call for analysts and investors, other than statements or characterizations of historical fact, are forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on our current expectations, estimates and projections about our industry and business, management’s beliefs, and certain assumptions made by us, all of which are subject to change. Forward-looking statements can often be identified by words such as “anticipates,” “expects,” “intends,” “plans,” “predicts,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” “would,” “could,” “potential,” “continue,” “ongoing,” similar expressions, and variations or negatives of these words. Examples of such forward-looking statements include, but are not limited to, the amount and timing of reduced research & development and selling, general & administrative expenses resulting from the exit of the cellular baseband business, the possibility of a sale or wind-down of such business, our ability to drive growth through our planned reinvestments in our Broadband, Infrastructure and Connectivity businesses, and guidance provided on future revenue, product gross margin and operating expenses for the second quarter of 2014 (on both a GAAP and non-GAAP basis). These forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause our actual results to differ materially and adversely from those expressed in any forward-looking statement.

These risks and uncertainties include, but are not limited to the following:

• Our quarterly operating results may fluctuate significantly.
• We depend on a few significant customers for a substantial portion of our revenue.
• We face intense competition.
• We manufacture and sell complex products and may be unable to successfully develop and introduce new products.
• We may fail to appropriately adjust our operations in response to changes in our strategy or market demand.
• We are exposed to risks associated with our international operations.
• Our business is subject to potential tax liabilities.
• Our stock price is highly volatile.
• Our operating results may be adversely impacted by worldwide economic uncertainties and specific conditions in the markets we address.
• We may be required to defend against alleged infringement of intellectual property rights of others and/or may be unable to adequately protect or enforce our own intellectual property rights.
• We face risks associated with our acquisition strategy.
• We may be unable to attract, retain or motivate key personnel.
• We are subject to order and shipment uncertainties.
• We depend on third parties to fabricate, assemble and test our products.
• Our systems are subject to security breaches and other cyber security incidents.
• Government regulation may adversely affect our business.
• Our co-founders and their affiliates may strongly influence the outcome of matters that require the approval of our shareholders.
• Our articles of incorporation and bylaws contain anti-takeover provisions.
• There can be no assurance that we will continue to declare cash dividends.
• We may be unable to successfully sell or wind down the cellular baseband business or realize the expected reduction in annualized research and development and selling, general and administrative expenses.
• There can be no assurance that we will be able to successfully grow or maintain our Connectivity business independent of the cellular baseband business.

Broadcom’s Annual Report on Form 10-K for the year ended December 31, 2013, subsequent Quarterly Reports on Form 10-Q, recent Current Reports on Form 8-K, and other Securities and Exchange Commission filings discuss the foregoing risks as well as other important risk factors that could contribute to such differences or otherwise affect our business, results of operations and financial condition. The forward-looking statements in this release speak only as of this date. We undertake no obligation to revise or update publicly any forward-looking statement to reflect future events or circumstances.

Broadcom has based the preceding guidance for the three months ending June 30, 2014 on expectations, assumptions and estimates that we believe are reasonable given our assessment of historical trends and other information reasonably available as of June 2, 2014. Our guidance consists of predictions only, however, and is subject to a wide range of known and unknown business risks and uncertainties, many of which are beyond our control. The forecasts and projections contained in the table above should not be regarded as representations by Broadcom that the estimated results will be achieved. Projections and estimates are necessarily speculative in nature and actual results may vary materially from the guidance we provide today. The non-GAAP guidance presented above is calculated in a manner consistent with the presentation of non-GAAP results as reported in our April 24, 2014 press release covering Broadcom’s first quarter 2014 results.

The guidance set forth in the above table should be read together with the information under the caption, “Cautions Regarding Forward-Looking Statements” above, our Annual Report on Form 10-K for the year ended December 31, 2013, subsequent Quarterly Reports on Form 10-Q, recent Current Reports on Form 8-K, and our other Securities and Exchange Commission filings. We undertake no obligation to publicly update or revise any forward-looking statements, including the guidance set forth herein, to reflect future events or circumstances.

Note Regarding Use of Non-GAAP Financial Measures

Broadcom believes that the presentation of the non-GAAP measures included herein provides important supplemental information to management and investors regarding financial and business trends relating to our financial condition and results of operations. Broadcom’s management believes that the use of these non-GAAP financial measures provides consistency and comparability among and between results from prior periods or forecasts and future prospects, and also facilitates comparisons with other companies in our industry, many of which use similar non-GAAP financial measures to supplement their GAAP results. Broadcom’s management has historically used these non-GAAP financial measures when evaluating operating performance, because we believe that the inclusion or exclusion of the items in these measures provides insight into our core operating results, our ability to generate cash and underlying business trends affecting our performance. Broadcom has chosen to provide this information to investors to enable them to perform additional analysis of past, present and future operating performance and as a supplemental means to evaluate our ongoing core operations. The non-GAAP financial information presented herein should be considered supplemental to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP.

Broadcom®, the pulse logo, Connecting everything®, the Connecting everything logo are among the trademarks of Broadcom Corporation and/or its affiliates in the United States, certain other countries and/or the EU. Any other trademarks or trade names mentioned are the property of their respective owners.

Contacts

(AQXP) xpansion of Ongoing Phase 2 Trials of AQX-1125

VANCOUVER, British Columbia, June 2, 2014  — Aquinox Pharmaceuticals, Inc. (Nasdaq:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics for inflammatory disease and cancer, today announced expansion of its ongoing Phase 2 clinical trials with its lead product candidate, AQX-1125.

The U.S. Food and Drug Administration (FDA) has accepted Aquinox’s Investigational New Drug (IND) application for the Phase 2 LEADERSHIP trial, which is investigating the safety and efficacy of AQX-1125 in reducing pain and urinary symptoms in patients with bladder pain syndrome/interstitial cystitis (BPS/IC). The LEADERSHIP trial has been enrolling patients at clinical sites across Canada and is now active at sites in the United States.

“The United States is an integral part of our development and commercialization plan for AQX-1125,” said David J. Main, President and Chief Executive Officer of Aquinox. “Expanding LEADERSHIP into the U.S. provided Aquinox with an important opportunity for the FDA to review our program while also broadening our access to patients for enrollment and engaging with leading U.S. clinicians.”

In addition, Aquinox announced that it is expanding its Phase 2 FLAGSHIP trial investigating the safety and efficacy of AQX-1125 in the treatment of exacerbations of chronic obstructive pulmonary disease (COPD) after having obtained regulatory clearance in Australia, where it is currently adding clinical sites. Aquinox is also seeking regulatory clearance to add clinical sites in New Zealand. FLAGSHIP has been enrolling patients at clinical sites across Northern and Central Europe.

“Australia and New Zealand have COPD prevalence and treatment practices that are similar to the countries where the FLAGSHIP trial is already underway and the added sites have contributed significantly to prior drug trials in COPD,” said Dr. Stephen Shrewsbury, Senior Vice President, Clinical Development and Chief Medical Officer of Aquinox. “Opening sites in the Southern Hemisphere will allow us to capitalize upon their winter season when patients typically experience an increase in COPD exacerbations.”

About Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC)

BPS/IC is a chronic inflammatory bladder disease characterized by pelvic pain and increased urinary urgency and/or frequency. For many sufferers, these symptoms are severe and adversely affect all major aspects of their lives, including overall physical and emotional health, employment, social and intimate relationships, and leisure activities. While the cause of the disease remains largely unknown, erosion of the bladder lining is thought to be a significant contributor. BPS/IC currently affects an estimated 14 million people in the United States. Most BPS/IC patients continue to suffer this debilitating condition, despite treatment with existing therapies. Most current therapies and those in development are focused solely on symptomatic relief of BPS/IC. New and innovative therapies that target the underlying disease processes to reduce the chronic pain and urinary symptoms are needed.

About the LEADERSHIP Trial

The LEADERSHIP trial is a double-blind, placebo-controlled, Phase 2 clinical trial investigating AQX-1125‘s ability to reduce pain and urinary symptoms in approximately 70 female patients with BPS/IC. The primary objective is to measure the difference in the change from baseline in the mean daily bladder pain score based on an 11-point numeric rating scale (NRS) at six weeks recorded by eDiary. For more information on the LEADERSHIP trial, please visit www.clinicaltrials.gov.

About Chronic Obstructive Pulmonary Disease (COPD) & Related Exacerbations.

COPD is a lung disease frequently associated with cigarette smoking and air pollution and is characterized by progressive loss of lung function and chronic inflammation of the airways. COPD currently affects up to an estimated 600 million people worldwide, with up to 200 million suffering from the moderate and severe forms that most frequently require treatment. It is the third leading cause of death in the United States and the fourth leading cause of death worldwide. In the United States alone, the annual economic burden of treating COPD is estimated at $50 billion. COPD patients suffer periodic episodes with severe worsening of symptoms, known as exacerbations. Of COPD patients, 22-40% die within one year of a severe exacerbation and 66% die within three years. Since exacerbations involve severe increased airway inflammation, treatment with potent anti-inflammatories is a potentially promising strategy to reduce exacerbations.

About the FLAGSHIP Trial

The FLAGSHIP trial is a multinational, double-blind, placebo-controlled, Phase 2 clinical trial investigating AQX-1125‘s ability to reduce the effects of exacerbations in approximately 400 unstable patients with moderate to severe COPD. The primary endpoint is the change in the severity, duration and reoccurrence of exacerbations in patients treated with AQX-1125 versus placebo, as measured by EXACT-PRO, a patient-reported outcome tool that measures symptoms. For more information on the FLAGSHIP trial, please visit www.clinicaltrials.gov.

About Aquinox Pharmaceuticals

Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation and cancer. Aquinox’s primary focus is advancing anti-inflammatory product candidates targeting SHIP1, a key regulator of the PI3K immune cell-signaling pathway. Aquinox’s lead product candidate, AQX-1125, is a SHIP1 activator that has demonstrated broad anti-inflammatory properties and has successfully completed three clinical trials with over 100 subjects dosed with once daily oral therapy. Aquinox is currently investigating AQX-1125 in two Phase 2 trials for chronic obstructive pulmonary disease (COPD) exacerbations and bladder pain syndrome/interstitial cystitis (BPS/IC), both debilitating chronic inflammatory diseases affecting millions of people worldwide. For more information please visit www.aqxpharma.com.

Cautionary Note on Forward-looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, relating to: the success and timing of our Phase 2 clinical trials; the outcome of our interactions with the FDA and other regulatory authorities; and potential market opportunities for AQXP-1125. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: our ability to enroll patients in our clinical trials at the pace that we project; the size and growth of the potential markets for AQX-1125 or any future product candidates and our ability to serve those markets; our ability to obtain and maintain regulatory approval of AQX-1125 or any future product candidates; and our expectations regarding the potential safety, efficacy or clinical utility of AQX-1125 or any future product candidates. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. More information about the risks and uncertainties faced by Aquinox is contained in the company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2014 filed with the Securities and Exchange Commission. Aquinox disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: Brendan Payne, Senior Manager, Investor Relations
         Aquinox Pharmaceuticals, Inc.
         604.629.9223
         ir@aqxpharma.com

         Bianca Nery
         MacDougall Biomedical Communications
         650.339.7533
         aquinox@macbiocom.com

(GIGA) High Performance Filter Extended to Third Aircraft Platform

SAN RAMON, Calif., June 2, 2014  — Giga-tronics Incorporated announced today that it has completed a sole-source multi-year agreement with a major aerospace company to develop a variant of its high performance fast tuning YIG filters for a third aircraft platform. In connection with the agreement, the Company has received orders valued at approximately $6.9 million for the non-recurring engineering and for the delivery of a limited number of flight-qualified prototype hardware.  The majority of the non-recurring engineering services are expected to be performed over the next twelve months. The Company is also anticipating an additional multi-year order later this year for approximately $10.0 million associated with the production units.

The award for developing the specialty filters based upon the Company’s fast switching YIG technology, will be fulfilled by Giga-tronics’ Microsource subsidiary co-located with the Company’s instrument division in San Ramon, California. John Regazzi, President and CEO of Giga-tronics, said “Engineers from our components group will produce a working filter in less than 12 months by leveraging Microsource’s F/A-18 and F-15E filter know-how. We are very proud to be chosen for this new program based upon our proven field performance on US Navy and US Air Force fighter jets.”

Giga-tronics Microsource has been supplying sole-sourced filters for a number of years. Ernie Nyiri, Microsource’s program manager, stated “The nature of sole sourced contracts requires   Microsource to maintain the highest customer satisfaction as measured by on time delivery product quality & reliability, and price. At the conclusion of the development phase, Microsource will be a supplier of filter systems for all three of the US designed 4^th generation fighters.”

Giga-tronics is a publicly held company, traded on the NASDAQ Capital Market under the symbol “GIGA”. Giga-tronics produces instruments, subsystems and sophisticated microwave components that have broad applications in defense electronics, aeronautics and wireless telecommunications.

This press release contains forward-looking statements concerning profitability, development of products, future growth, shareholder value, backlog and shipments. Actual results may differ significantly due to risks and uncertainties, such as future orders, cancellations or deferrals, disputes over performance, availability of capital and capital resources, the ability to collect receivables and general market conditions. For further discussion, see Giga-tronics’ most recent annual report on Form 10-K for the fiscal year ended March 30, 2013, Part I, under the heading “Risk Factors” and Part II, under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

CONTACT: Steven D. Lance
         Vice President of Finance/Chief Financial Officer
         slance@gigatronics.com
         (925) 302-1056